Clinical trial • Phase I • Oncology
XmAb24306 for Locally advanced or metastatic solid tumors
Phase I trial of XmAb24306 for Locally advanced or metastatic solid tumors. open-label, none/not specified-controlled, adaptive. 176 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Locally advanced or metastatic solid tumors
- Trial Stage
- Phase I
- Drug Modality
- Other | Monoclonal antibody
Key dates
- Initial CTIS Submission Date
- 19-03-2024
- First CTIS Authorization Date
- 15-04-2024
Trial design
open-label, none/not specified-controlled, adaptive Phase I trial across 12 sites in Belgium, Spain, Netherlands and others.
- Open Label
- Yes
- Comparator
- None/Not specified
- Adaptive
- True - dose-escalation design (dose-escalation elements implied by study title)
- Single Multiple Or Escalation Dose Combined
- Yes
- Target Sample Size
- 176
Recruitment
- Planned Sample Size
- 176
- Recruitment Window Months
- 50
Geography
- Total Number Of Sites
- 12
- Total Number Of Participants
- 99
Belgium
- Latest Decision Or Authorization Date
- 01-09-2025
- Number Of Sites
- 1
- Number Of Participants
- 7
Sites
- Site Name
- GasthuisZusters Antwerpen
- Department Name
- Medical Oncology
- Principal Investigator Name
- Tom Van den Mooter
- Principal Investigator Email
- tom.vandenmooter@gza.be
- Contact Person Name
- Tom Van den Mooter
- Contact Person Email
- tom.vandenmooter@gza.be
Spain
- Latest Decision Or Authorization Date
- 28-04-2026
- Number Of Sites
- 5
- Number Of Participants
- 38
Sites
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Servicio de Oncologia
- Principal Investigator Name
- Ignacio Melero Bermejo
- Principal Investigator Email
- imelero@unav.es
- Contact Person Name
- Ignacio Melero Bermejo
- Contact Person Email
- imelero@unav.es
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Servicio de Oncologia
- Principal Investigator Name
- Victor Moreno Garcia
- Principal Investigator Email
- victor.moreno@startmadrid.com
- Contact Person Name
- Victor Moreno Garcia
- Contact Person Email
- victor.moreno@startmadrid.com
- Site Name
- Hospital General Universitario Reina Sofia
- Department Name
- Servicio de Oncologia
- Principal Investigator Name
- Rosa Rodriguez Alonso
- Principal Investigator Email
- rosarodriguezalonso@gmail.com
- Contact Person Name
- Rosa Rodriguez Alonso
- Contact Person Email
- rosarodriguezalonso@gmail.com
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Servicio de Oncologia
- Principal Investigator Name
- Ignacio Melero Bermejo
- Principal Investigator Email
- imelero@unav.es
- Contact Person Name
- Ignacio Melero Bermejo
- Contact Person Email
- imelero@unav.es
- Site Name
- Hospital Clinico Universitario De Valencia
- Department Name
- Servicio de Oncologia
- Principal Investigator Name
- Andres Cervantes Ruiperez
- Principal Investigator Email
- andres.cervantes@uv.es
- Contact Person Name
- Andres Cervantes Ruiperez
- Contact Person Email
- andres.cervantes@uv.es
Netherlands
- Latest Decision Or Authorization Date
- 24-04-2026
- Number Of Sites
- 3
- Number Of Participants
- 35
Sites
- Site Name
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Department Name
- Medical Oncology
- Principal Investigator Name
- Neeltje Steeghs
- Principal Investigator Email
- fase1@nki.nl
- Contact Person Name
- Neeltje Steeghs
- Contact Person Email
- fase1@nki.nl
- Site Name
- Amsterdam UMC Stichting
- Department Name
- Medical Oncology
- Principal Investigator Name
- Mariette Labots
- Principal Investigator Email
- medonc-phase1@amsterdamumc.nl
- Contact Person Name
- Mariette Labots
- Contact Person Email
- medonc-phase1@amsterdamumc.nl
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Medical Oncology
- Principal Investigator Name
- Elisabeth de Vries
- Principal Investigator Email
- e.g.e.de.vries@umcg.nl
- Contact Person Name
- Elisabeth de Vries
- Contact Person Email
- e.g.e.de.vries@umcg.nl
Italy
- Latest Decision Or Authorization Date
- 12-05-2026
- Number Of Sites
- 3
- Number Of Participants
- 19
Sites
- Site Name
- Fondazione IRCCS Istituto Nazionale Dei Tumori
- Department Name
- SC Oncologia Medica I
- Principal Investigator Name
- Massimo Di Nicola
- Principal Investigator Email
- massimo.dinicola@istitutotumori.mi.it
- Contact Person Name
- Massimo Di Nicola
- Contact Person Email
- massimo.dinicola@istitutotumori.mi.it
- Site Name
- Istituto Europeo Di Oncologia S.r.l.
- Department Name
- Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative
- Principal Investigator Name
- Curigliano Giuseppe
- Principal Investigator Email
- giuseppe.curigliano@ieo.it
- Contact Person Name
- Curigliano Giuseppe
- Contact Person Email
- giuseppe.curigliano@ieo.it
- Site Name
- Humanitas Research Hospital
- Department Name
- Unità Operativa di Oncologia ed Ematologia
- Principal Investigator Name
- Simonelli Matteo
- Principal Investigator Email
- matteo.simonelli@humanitas.it
- Contact Person Name
- Simonelli Matteo
- Contact Person Email
- matteo.simonelli@humanitas.it
Sponsor
Primary sponsor
- Full Name
- Genentech Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- XmAb24306
- Active Substance
- XmAb24306
- Modality
- Other
- Investigational Product Name
- Atezolizumab
- Active Substance
- Atezolizumab
- Modality
- Monoclonal antibody
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- PATRITUMAB DERUXTECAN for Locally advanced or metastatic solid tumors
- ABBV-400 for Locally advanced or metastatic solid tumors
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer